Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Porter

Showing results (531-540 of 676) with videos related to

Pageof 68
Sort By:
Frontiers in Pharmacology|May 2, 2022
Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic TransportTim Quach, Luojuan Hu, Sifei Han, et al.
British Journal of Pharmacology|September 28, 1999
Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cellsR H Porter, K R Benwell, H Lamb, et al.
ACS Applied Materials & Interfaces|July 21, 2021
Quantitatively Tracking Bio-Nano Interactions of Metal-Phenolic Nanocapsules by Mass CytometryShiyao Li, Yi Ju, Jiajing Zhou, et al.
Biodemography and Social Biology|December 15, 2015
Validation of Biomarkers of CVD Risk from Dried Blood Spots in Community-Based Research: Methodologies and Study-Specific Serum EquivalenciesLaura B Samuelsson, Martica H Hall, Shakir McLean, et al.
Angewandte Chemie (International Ed. in English)|August 3, 2016
Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral BioavailabilityLuojuan Hu, Tim Quach, Sifei Han, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 7, 2019
Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulationEnyuan Cao, Anna Lindgren, Sofia Martinsson, et al.
Frontiers in Pharmacology|September 22, 2022
Corrigendum: Triglyceride-mimetic prodrugs of buprenorphine enhance oral bioavailability via promotion of lymphatic transportTim Quach, Luojuan Hu, Sifei Han, et al.
Pharmaceutical Research|June 6, 2022
Biocompatible Cationic Lipoamino Acids as Counterions for Oral Administration of API-Ionic LiquidsAnthony Lai, Nathania Leong, Dan Zheng, et al.
International Journal of Pharmaceutics|February 13, 2021
Stabilising disproportionation of lipophilic ionic liquid salts in lipid-based formulationsAnthony Lai, Yasemin Sahbaz, Leigh Ford, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 28, 2011
A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systemsLisa M Kaminskas, Victoria M McLeod, Brian D Kelly, et al.
Pageof 68

Showing results (531-540 of 676) with videos related to

Sort By:
Pageof 68
Frontiers in Pharmacology|May 2, 2022
Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic TransportTim Quach, Luojuan Hu, Sifei Han, et al.
British Journal of Pharmacology|September 28, 1999
Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cellsR H Porter, K R Benwell, H Lamb, et al.
ACS Applied Materials & Interfaces|July 21, 2021
Quantitatively Tracking Bio-Nano Interactions of Metal-Phenolic Nanocapsules by Mass CytometryShiyao Li, Yi Ju, Jiajing Zhou, et al.
Biodemography and Social Biology|December 15, 2015
Validation of Biomarkers of CVD Risk from Dried Blood Spots in Community-Based Research: Methodologies and Study-Specific Serum EquivalenciesLaura B Samuelsson, Martica H Hall, Shakir McLean, et al.
Angewandte Chemie (International Ed. in English)|August 3, 2016
Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral BioavailabilityLuojuan Hu, Tim Quach, Sifei Han, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 7, 2019
Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulationEnyuan Cao, Anna Lindgren, Sofia Martinsson, et al.
Frontiers in Pharmacology|September 22, 2022
Corrigendum: Triglyceride-mimetic prodrugs of buprenorphine enhance oral bioavailability via promotion of lymphatic transportTim Quach, Luojuan Hu, Sifei Han, et al.
Pharmaceutical Research|June 6, 2022
Biocompatible Cationic Lipoamino Acids as Counterions for Oral Administration of API-Ionic LiquidsAnthony Lai, Nathania Leong, Dan Zheng, et al.
International Journal of Pharmaceutics|February 13, 2021
Stabilising disproportionation of lipophilic ionic liquid salts in lipid-based formulationsAnthony Lai, Yasemin Sahbaz, Leigh Ford, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|June 28, 2011
A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systemsLisa M Kaminskas, Victoria M McLeod, Brian D Kelly, et al.
Pageof 68